Comparison of conditioning regimen toxicities among autologous stem cell transplantation eligible multiple myeloma patients: High-dose melphalan versus high-dose melphalan and bortezomib


Aypar E., Izzettin F. V. , Aki S. Z. , SANCAR M., Yegin Z. A. , Turkoz-Sucak G.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.24, no.4, pp.281-289, 2018 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 24 Issue: 4
  • Publication Date: 2018
  • Doi Number: 10.1177/1078155217697486
  • Title of Journal : JOURNAL OF ONCOLOGY PHARMACY PRACTICE
  • Page Numbers: pp.281-289

Abstract

Background Autologous hematopoietic stem cell transplantation (AHSCT) remains the standard of care for younger patients with multiple myeloma (MM). Currently, high-dose melphalan (HDM) is recommended as conditioning regimen before AHSCT. Preclinical data suggest that combining bortezomib and melphalan has synergistic effect against multiple myeloma cells. Bortezomib and HDM (Bor-HDM) combination as conditioning regimen has been investigated by many other investigators.